Professor Bernd Möbius is a leading academic in Phonetics and Phonology at the Department of Language Science and Technology, Saarland University. His research bridges phonetic theory with speech technology applications, focusing on text-to-speech systems, prosody modeling, and computational simulations of speech processes. Current research projects: DFG SFB 1102, C1: Information density and phonetic structure predictability DFG SFB 1102, C4: Slavic intercomprehension and surprisal theory (INCOMSLAV) Research Themes: Key areas include text-to-speech synthesis, speech prosody analysis, experimental methods in speech production/perception, information density in phonetics, and cross-linguistic studies of Slavic-Germanic languages. Scientific Contributions: Recent work explores Parkinson-induced dysarthria detection, breath noise acoustics, surprisal-driven speech behaviors, multilingual BERT models for idiomaticity, and perceptual consequences of acoustic adjustments.
Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Sandro Carrara is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Bio/CMOS Interfaces (BCI) laboratory. He is affiliated with the School of Engineering (STI), the Institute of Electrical Engineering (SCI-STI-SC), and the Integrated Systems Laboratory (LSI). His academic leadership spans teaching, doctoral supervision, and editorial roles in major journals including IEEE Sensors Journal and BioNanoScience. Education: Diploma in Electronics, National Technical Institute of Albenga, Italy Master in Physics, University of Genoa, Italy PhD in Biochemistry and Biophysics, University of Padua, Italy His research focuses on the integration of biological systems with CMOS technology, particularly in the development of nanoscale biosensors for health monitoring. Key areas include memristive biosensors, wearable and implantable sensors, electrochemical detection, and therapeutic drug monitoring. His work bridges electronics, nanotechnology, and biomedicine to enable point-of-care diagnostics and personalized medicine. His recent publications (2023–2025) show a strong trend toward sustainable printed electronics, machine learning for biosensing, in-memory computing for cancer diagnostics, and remote health monitoring. These works appear in high-impact journals such as IEEE Sensors Journal , Nanoscale , and Biosensors and Bioelectronics: X . Scientific Awards: IEEE Fellow (2015) IEEE Sensors Council Technical Achievement Award (2016) Distinguished Lecturer, IEEE Sensors Council (2017) Best Paper Award, IEEE MeMeA Symposium (2020) Multiple Gold and Bronze Leaf Prizes at PRIME and IEEE conferences Best Poster Awards at EMBEC and Nano-Tera meetings He actively advises PhD students and leads research projects involving CMOS-based biosensors, wireless implants, and smart sensor systems. His lab collaborates widely across disciplines and institutions, focusing on real-world applications in oncology, neurology, and environmental health. He has also contributed to the development of battery-free wearable devices, optical power transfer systems, and IoT-enabled telemedicine platforms. Laboratories and Teams: Bio/CMOS Interfaces (BCI) Laboratory, EPFL Integrated Systems Laboratory (LSI), EPFL Collaborations with IEEE Sensors Council and Circuits and Systems Society Editorial leadership in IEEE Sensors Journal and BioNanoScience
Professor Chris Holmes is a Professor of Biostatistics at the University of Oxford, where he moved from Imperial College London in February 2004. He is a Fellow at St Anne's College and works in the Department of Statistics. His research focuses on applications and statistical methods development in genomic sciences and genetic epidemiology, holding a prestigious Programme Leaders Grant in Statistical Genomics from the Medical Research Council. Prior to his position at Oxford, Professor Holmes completed his doctorate in Bayesian statistics at Imperial College London, investigating novel nonlinear pattern recognition methods. This was followed by a post-doctoral position and then a lectureship at Imperial. Before his academic career, he worked in industry for several years in scientific computing, developing techniques for real-time pattern recognition models in defense and SCADA systems. Professor Holmes has a broad interest in the theory, methods and applications of statistics and statistical modeling, with a particular foundation in Bayesian statistics which he views as providing a unified framework for stochastic modeling and information processing. His specific research interests include: Bayesian statistics and stochastic simulation Markov chain Monte Carlo methods Pattern recognition and nonlinear, nonparametric methods Spatial statistics Statistical genetics and genomics Genetic epidemiology His recent publications (2023-2025) demonstrate a strong focus on the intersection of biostatistics, artificial intelligence, and healthcare applications. His work spans multiple domains including AI-driven disease classification in neurology, genomic data analysis for health equity, machine learning tools for healthcare prediction, and addressing bias in medical AI systems. A notable trend across his research is the application of advanced statistical methods to solve pressing problems in genomics, epidemiology, and medical diagnostics, with an increasing emphasis on health equity and the ethical implications of AI in healthcare. Professor Holmes currently supervises PhD students Oscar Clivio, Sahra Ghalebikesabi, and Natalia Garcia Martin. His research is supported by multiple grants, including the MRC Programme Leaders Grant in Statistical Genomics which funds his work in statistical genomics. He is actively involved in three research groups at Oxford that reflect the breadth of his scholarly interests: Computational Statistics and Machine Learning Statistical Genetics and Epidemiology Statistical Theory and Methodology
Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it
Associate Professor Adam Irwin is an NHMRC Emerging Leadership Fellow and Associate Professor in Infectious Diseases at the University of Queensland (UQ) and Queensland Children’s Hospital. He holds positions within the UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences. His work focuses on early sepsis recognition, antimicrobial stewardship, and pediatric infectious diseases. Dr. Irwin completed his medical degree at the University of Birmingham and his PhD in 2016 from the University of Liverpool’s Institute of Infection and Global Health. He has led initiatives like the Queensland Paediatric Sepsis Program, recognized with a Global Sepsis Alliance Award and Queensland Health Excellence Awards. His research spans sepsis pathway implementation, antimicrobial resistance trends, and rapid diagnostic tools. Notable grants include NHMRC funding for studies on multi-drug resistant infections and Children’s Hospital Foundation support for genomics and antimicrobial stewardship projects. He supervises PhD candidates in areas like bloodstream infections and molecular diagnostics. Dr. Irwin collaborates across institutions, contributing to projects such as the RAPIDS Study Group and the PAEDS surveillance network. Awards include the NHMRC Emerging Leadership Fellowship and recognition for sepsis program excellence. His work emphasizes translating research into clinical practice, improving outcomes for critically ill children through evidence-based protocols and innovative diagnostics.
Martin T. Wells is the Charles A. Alexander Professor of Statistical Sciences at Cornell University, with joint appointments in the Department of Statistical Science, Department of Biological Statistics and Computational Biology, Department of Social Statistics, and as Professor of Clinical Epidemiology and Health Services Research at Weill Medical School. He serves as Editor-in-Chief of the ASA-SIAM Book Series and Co-Editor of the Journal of Empirical Legal Studies. Cornell University, Ithaca, NY Weill Cornell Medical College Research Interests span applied and theoretical statistics, Bayesian methods, biostatistics, clinical epidemiology, and computational biology. His work bridges disciplines like finance, legal studies, and health services research. Article Trends highlight advancements in Bayesian modeling, quantum cognition machine learning, tensor analysis, and misclassification correction, with applications in genomics, finance, and public health. Fellow of the American Statistical Association Fellow of the Royal Statistical Society Contributions include developing statistical software (e.g., rTensor), methodological innovations in clinical trials, and empirical legal studies on civil rights and the death penalty.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.
Najim Dehak is an Associate Professor in the Department of Electrical and Computer Engineering at Johns Hopkins University, part of the Whiting School of Engineering. His research focuses on machine learning applied to speech processing, audio classification, and health applications. He is renowned for developing the I-vector representation for speaker recognition, introduced in 2008 during a workshop at Johns Hopkins’ Center for Language and Speech Processing. Prior to this role, he was a research scientist at MIT’s Computer Science and Artificial Intelligence Laboratory. Dehak holds a PhD from the School of Advanced Technology in Montreal (2009). He is a Senior Member of IEEE and contributes to the IEEE Speech and Language Technical Committee. His work bridges AI, healthcare, and signal processing, with notable contributions to neurodegenerative disease detection via speech and handwriting analysis. Research interests include adversarial attacks on speech systems, multimodal biomarker discovery, and robust speech processing across demographics. His lab’s tools, like the Hermespeech Recorder, enable scalable data collection for clinical and research applications. Education: PhD in Advanced Technology (2009), Montreal Affiliations: Johns Hopkins University, IEEE Labs/Teams: Center for Language and Speech Processing (CLSP) His recent work explores AI’s role in aging research, including Alzheimer’s and Parkinson’s disease detection through speech, eye tracking, and handwriting analysis. Ongoing projects address fairness in speaker verification and robustness against adversarial attacks in ASR systems.
David Erickson is the SC Thomas Sze Director and Sibley College Professor at Cornell University's Sibley School of Mechanical and Aerospace Engineering. He also holds a joint professorship in the Division of Nutritional Sciences. His research focuses on global health technologies, medical diagnostics, microfluidics, photonics, nanotechnology, and energy systems. He previously served as Associate Dean of Engineering for Research and Graduate Programs. Erickson leads the NIH-funded PORTENT Center for Point-of-Care Technologies in Global Health and has co-founded companies like Dimensional Energy and VitaScan to commercialize diagnostic and energy technologies. Education: B.Sc., Mechanical Engineering, University of Alberta (1999) M.A.Sc., Mechanical Engineering, University of Toronto (2001) Ph.D., Mechanical Engineering, University of Toronto (2004) Postdoctoral Scholar, Electrical Engineering, California Institute of Technology (2005) Research Interests: Erickson’s work spans global health diagnostics , nanobio applications , and clean energy innovation . He develops portable medical devices for low-resource settings, including smartphone-integrated diagnostic tools for malaria, iron deficiency, and cancer. His lab also pioneers photothermal reactors for CO2 conversion into sustainable fuels. Key areas include: Point-of-care testing for infectious diseases and nutritional deficiencies Nanofluidic and optofluidic technologies for biomolecular analysis Solar-driven energy systems for carbon-neutral fuels Awards: Presidential Early Career Award for Scientists and Engineers (2011) Fellowships from the Optical Society, ASME, and Canadian Academy of Engineering Carbon X-Prize Finalist (2019) for Dimensional Energy’s CO2-to-fuel technology Grants & Industry Collaboration: Erickson’s research is funded by NIH, NSF, ARPA-E, DOE, and USAID. His lab’s innovations have spun off start-ups addressing global health and energy challenges. Notable projects include: - Portable cancer diagnostics in sub-Saharan Africa using mobile phone-based systems - Solar-powered CO2 conversion reactors tested in Wyoming and Arizona Labs & Teams: The Erickson Lab collaborates with the Cornell Atkinson Center for Sustainability and the McGovern Center for Entrepreneurship. Key initiatives include the PORTENT Center and the Dimensional Energy CO2-to-fuel project.
Thomas R Overton serves as Department Chair and Professor of Dairy Nutrition and Management in the Department of Animal Science at Cornell University's College of Agriculture and Life Sciences (CALS). He also directs PRO-DAIRY, an extension program focused on enhancing dairy farm profitability and efficiency in New York through research-based strategies for transition cow management. Education: Doctorate, University of Illinois, 1998 Master of Science, University of Illinois, 1994 Bachelor of Science, Cornell University, 1991 Dr. Overton's research centers on the transition period (late pregnancy to early lactation) in dairy cows—the most critical phase for health and productivity. His work integrates nutritional physiology with practical farm applications, targeting hypocalcemia management, protein supplementation strategies, inflammation control, and biomarker validation for metabolic health. This research directly informs his extension efforts through PRO-DAIRY, which delivers actionable knowledge to dairy producers and industry professionals. Analysis of his 15 most recent publications (2022-2024) reveals consistent emphasis on transition cow nutrition, with growing focus on metabolic analytics, precision feeding, and real-world herd management. His work bridges controlled studies at Cornell's Ruminant Center with observational research on commercial New York dairy farms. Scientific Awards: 2024 Nutrition Professionals Applied Dairy Research Award (American Dairy Science Association) 2010 CALS Extension/Outreach Team Award (PRO-DAIRY) 2007 Foundation Scholar Award (American Dairy Science Association) 2007 CALS Extension/Outreach Team Award Dr. Overton advises undergraduate and graduate students in Animal Science while leading PRO-DAIRY's extension initiatives. His program secures industry partnerships and grants focused on improving dairy farm sustainability through nutritional science. The July 2025 'Farm of the Future' showcase at Cornell's Ruminant Center exemplifies his commitment to translating research into practical innovation. He operates within Cornell's PRO-DAIRY program and the Cornell University Ruminant Center—a living laboratory for dairy technology testing—collaborating closely with industry stakeholders to address emerging challenges in dairy production.
Clifton R. Haider, Ph.D., is a Professor of Biomedical Engineering at Mayo Clinic, holding primary appointments as a Consultant in the Department of Physiology & Biomedical Engineering and the Department of Pediatric and Adolescent Medicine. His research focuses on accelerating medical device development through a discovery platform integrating mathematical modeling, algorithmic design, and physiological sensor validation. This platform aims to identify predictive biomarkers for conditions like cardiovascular collapse, sleep disorders, and neurodegenerative diseases. Dr. Haider’s work emphasizes noninvasive, autonomous monitoring and real-time predictive algorithms, with a particular focus on pediatric care. Education: PhD, Physiology & Biomedical Engineering, Mayo Graduate School, Mayo Clinic College of Medicine Predoctoral Studies in Biomedical Engineering and Physiology, Mayo Graduate School BSc (Hons), Biomedical Engineering, University of Iowa Research Interests: Dr. Haider’s work bridges engineering and clinical practice, targeting unmet needs in pediatric and adult healthcare. His discovery platform combines statistical modeling, sensor design, and validation to streamline medical device prototyping. Key focus areas include: Accelerated medical device design Quantitative predictive biomarkers Remote pediatric monitoring Real-time algorithm development This platform seeks to predict treatment responses and identify patients requiring advanced care, enhancing clinical decision-making. Awards: Office of Naval Research Young Investigator Program (2014–present) Grants & Labs: His research is supported by interdisciplinary collaborations at Mayo Clinic, leveraging laboratory facilities for sensor validation and algorithm testing. While specific grant details are not listed, his work aligns with Mayo’s emphasis on translational biomedical engineering.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
